COMPOSITION CONTAINING ADIPOSE STEM CELL-DERIVED EXOSOMES AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING LIVER FIBROSIS

• US 20190314419A1
• Filed: 11/21/2017
• Published: 10/17/2019
• Est. Priority Date: 11/21/2016
• Status: Active Grant

• Current Assignee: Exostemtech Co., Ltd.
• Original Assignee: Exostemtech Co., Ltd.
• Inventors: PARK, Jae Hyung, LEE, Hansang, HEO, Roun, HAN, Hwa Seung
• Granted Patent: US 11,241,459 B2
• Time in Patent Office: Days
• CPC Class Codes: A23L 33/10 using additives addition of substantially indigestible substances A23L33/21
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/32 having an effect on the health of the digestive tract
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present embodiment relates to a composition containing human adipose stem cell-derived exosomes as an active ingredient for preventing, alleviating or treating liver fibrosis. The adipose stem cell-derived exosomes according to the present embodiment carry genetic information, protein, growth factor and the like for treating liver fibrosis, and have shown excellent results in treating liver fibrosis in animal models therefor, and, being a cell-derived substance, exosomes have the advantages of being highly biocompatible and having a superb absorption rate.

Claims

1. A pharmaceutical composition for preventing or treating liver fibrosis, comprising adipose stem cell-derived exosomes as an active ingredient.

2. The pharmaceutical composition according to claim 1,

wherein the adipose stem cell is human adipose stem cell.

3. The pharmaceutical composition according to claim 1,

wherein the pharmaceutical composition reduces a level of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin (TP), or LW/BW (Ratio of liver weight to body weight) in blood.

4. A method for preventing or treating liver fibrosis, comprising administering a pharmaceutical composition comprising adipose stem cell-derived exosomes as an active ingredient to a subject.

5. (canceled)

6. A health functional food composition for alleviating liver fibrosis, comprising adipose stem cell-derived exosomes as an active ingredient.

7. The health functional food composition according to claim 6,

wherein the adipose stem cell is human adipose stem cell.